

WEBINAR SERIES 2020 - 2021

Gene therapy, clinical trials and new developments in IRD research

- Date: Saturday 17th October
- **Time:** 2.00pm EST (1.30pm in SA, 12.30pm in NT, 1.00pm in QLD and 11.00am in WA), following the Annual General Meeting.
- **Cost:** Free for current Retina Australia members

\$15 for non-members

The regulatory approval and commercialisation of Luxturna in 2017 has opened the floodgates for gene therapy, with numerous clinical trials underway or rapidly approaching. Dr Tom Edwards and Dr Lauren Ayton will update Retina Australia members on the national approach to identifying and characterising people who might be eligible for these trials (through the Inherited Retinal Disease Natural History Study), as well as describing the most promising developments in the field.

Presenters:

Dr Lauren Ayton is currently collaborating with Dr Thomas Edwards and Prof Keith Martin on exciting new gene therapy programs for inherited retinal degenerations. Her research group also work on non-invasive low-vision interventions, such as electronic aids and sensory substitution devices.

Dr Tom Edwards Tom is a Melbourne-based vitreoretinal surgeon. He leads a research team investigating retinal gene therapy at the University of Melbourne affiliated Centre for Eye Research Australia (CERA) based at the Royal Victoria Eye and Ear Hospital. He is also a senior clinician in the RVEEH Ocular Genetics Clinic.

To participate in this event, you can connect via the internet or using your phone, either mobile or landline. To reserve a place, or if you would like more information about how webinars work, simply send an email with your name and contact details to <u>info@retinaaustralia.com.au</u>, or phone our office on 03-9650 5088.